| Formulary Chapter 5: Infections - Full Chapter
|
|
| Chapter Links... |
 NICE NG199: Clostridioides difficile infection: antimicrobial prescribing |
| NICE NG15: Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use |
| NICE NG79: Sinusitis (acute): antimicrobial prescribing |
| NICE NG79: Sinusitis (acute): antimicrobial prescribing (visual summary) |
 Summary of antimicrobial prescribing guidance - managing common infections |
| Details... |
| 05.03 |
Antiviral drugs |
|
|
Molnupiravir
(Oral )
|
Formulary
|
|
|
|
Peginterferon Alfa
|
Formulary
|
Hospital only
In line with NICE
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
|
Peginterferon Alfa (Pegasys®)
|
Formulary
|
Hospital only
In line with NICE
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
|
Remdesivir (Veklury®)
(IV)
|
Formulary
|
|
|
|
| 05.03.01 |
HIV infection |
|
|
| 05.03.01 |
Nucleoside reverse transcriptase inhibitors |
|
|
Abacavir
(Tablets)
|
Formulary
|
|
|
|
Abacavir and Lamivudine
|
Formulary
|
|
|
|
Abacavir with dolutegravir and lamivudine (Triumeq ®)
(Tablets)
|
Formulary
|
|
|
|
Efavirenz with emtricitabine and tenofovir disoproxil
|
Formulary
|
|
|
|
Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide (Genvoya®)
|
Formulary
|
|
|
|
Emtricitabine (Emtriva®)
(Oral presentations)
|
Formulary
|
|
|
|
Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg (Eviplera®)
|
Formulary
|
Blueteq /prior approval form
|
|
|
Emtricitabine with rilpivirine and tenofovir alafenamide ( Odefsey® )
|
Formulary
|
|
|
|
Emtricitabine with tenofovir alafenamide (Descovy®)
|
Formulary
|
|
|
|
Emtricitabine with tenofovir disoproxil
|
Formulary
|
|
|
|
Lamivudine
|
Formulary
|
|
|
|
Lamivudine (Epivir®, Zeffix®)
|
Formulary
|
|
|
|
Lamivudine with dolutegravir (Dovato®)
(Oral )
|
Formulary
|
|
|
|
Lamivudine with tenofovir disoproxil and doravirine (Delstrigo®)
(Oral )
|
Formulary
|
|
|
|
Rilpivirine hydrochloride (Edurant®)
(tablets)
|
Formulary
|
|
|
|
Rilpivirine hydrochloride (Rekambys®)
(IV)
|
Formulary
|
|
|
|
Tenofovir, cobicistat, elvitegravir & emtricitabine (Stribild®)
|
Formulary
|
|
|
|
Zidovudine
(capsules )
|
Formulary
|
|
|
|
Zidovudine (Retrovir®)
(IV & SF solution)
|
Formulary
|
|
|
|
Zidovudine and Lamivudine
(tablets)
|
Formulary
|
|
|
|
| 05.03.01 |
Protease inhibitors |
|
|
Atazanavir
(capsules)
|
Formulary
|
|
|
|
Atazanavir with cobicistat (Evotaz®)
|
Formulary
|
Blueteq /prior approval form
|
|
|
Baloxavir marboxil
(Tablets)
|
Formulary
|
|
|
|
Bictegravir with emtricitabine and tenofovir alafenamide (Biktarvy®)
|
Formulary
|
|
|
|
Darunavir
|
Formulary
|
|
|
|
Darunavir with cobicistat (Rezolsta®)
|
Formulary
|
Blueteq /prior approval form
|
|
|
Darunavir with cobicistat, emtricitabine and tenofovir alafenamide (Symtuza®)
|
Formulary
|
Blueteq /prior approval form
|
|
|
Dolutegravir (Tivicay ®)
|
Formulary
|
|
|
|
Dolutegravir with rilpivirine (Juluca®)
|
Formulary
|
|
|
|
Fosamprenavir (Telzir®)
(tablets)
|
Formulary
|
|
|
|
Lopinavir and Ritonavir (Kaletra®)
(tablets & solution)
|
Formulary
|
|
|
|
Lopinavir with Ritonavir
(Oral )
|
Formulary
|
|
|
|
Nirmatrelvir With Ritonavir
|
Formulary
|
|
|
|
Ritonavir
(Oral presentations)
|
Formulary
|
|
|
|
| 05.03.01 |
Non-nucleoside reverse transcriptase inhibitors |
|
|
Doravirine (Pifeltro®)
|
Formulary
|
|
|
|
Etravirine (Intelence®)
(tablets)
|
Formulary
|
|
|
|
Nevirapine
|
Formulary
|
|
|
|
Nevirapine (Viramune®)
(tablets, extended release tablets & suspension)
|
Formulary
|
|
|
|
| 05.03.01 |
Other antiretrovirals |
|
|
Cabotegravir (Vocabria®)
|
Formulary
|
In line with NICE
|
NICE TA757: Cabotegravir with rilpivirine for treating HIV-1
|
Elbasvir with grazoprevir (Zepatier®)
|
Formulary
|
|
|
|
Enfuvirtide (Fuzeon®)
|
Formulary
|
|
|
|
Maraviroc
(tablets)
|
Formulary
|
|
|
|
Maraviroc (Celsentri®)
(tablets)
|
Formulary
|
|
|
|
Raltegravir (Isentress ®)
(tablets)
|
Formulary
|
|
|
|
| 05.03.01 |
Pharmacokinetic enhancers of antiretrovirals |
|
|
Cobicistat (Tybost ®)
|
Formulary
|
|
|
|
| 05.03.01 |
Combination Products |
|
|
| 05.03.02 |
Herpesvirus infections |
|
|
Aciclovir lauriad (Sitavig)
|
Formulary
|
|
|
|
| 05.03.02.01 |
Herpes simplex and varicella-zoster infection |
|
|
Famciclovir
(Oral )
|
Second Choice
|
Second line for Shingles
|
|
|
Valaciclovir
(Oral presentations)
|
Second Choice
|
To be used in exceptional cases only
Least cost effective option
Second line for shingles if compliance is a problem
£££££
|
|
|
Aciclovir
(injection)
|
Formulary
|
|
|
|
Aciclovir
(Oral presentations)
|
Formulary
|
Tablets most cost effective choice
Dispersible tablets £
Suspension ££
|
|
|
Inosine Pranobex (Imunovir®)
|
Formulary
|
|
|
|
| 05.03.02.02 |
Cytomegalovirus infection |
|
|
Cidofovir
|
Formulary
|
|
|
|
Foscarnet Sodium
(infusion)
|
Formulary
|
|
|
|
Foscarnet Sodium (Foscavir®)
(infusion)
|
Formulary
|
|
|
|
Ganciclovir
(infusion)
|
Formulary
|
|
|
|
Ganciclovir (Cymevene®)
(infusion)
|
Formulary
|
|
|
|
Letermovir (Prevymis®)
|
Formulary
|
In line with NICE
|
NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant
|
Valganciclovir
(Oral presentations)
|
Formulary
|
|
|
|
| 05.03.03 |
Viral hepatitis |
|
|
Adefovir Dipivoxil (Hepsera®)
|
Formulary
|
|
NICE CG165: Hepatitis B (chronic) - diagnosis and management
NICE TA96: Adefovir dipivoxil and peginterfeon alfa-2a for the treatment of chronic hepatitis B
|
Entecavir
|
Formulary
|
|
NICE CG165: Hepatitis B (chronic) - diagnosis and management
NICE TA153: Entecavir for the treatment of chronic hepatitis B
|
Entecavir (Baraclude®)
|
Formulary
|
|
NICE CG165: Hepatitis B (chronic) - diagnosis and management
NICE TA153: Entecavir for the treatment of chronic hepatitis B
|
| 05.03.03.01 |
Chronic hepatitis B |
|
|
Tenofovir alafenamide (Vemlidy®)
|
Formulary
|
|
|
|
Tenofovir Disproxil
(Oral presentations)
|
Formulary
|
|
|
|
| 05.03.03.02 |
Chronic hepatitis C |
|
|
Glecaprevir-pibrentasvir (Maviret®)
|
Formulary
|
In line with NICE
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
|
Ledipasvir/sofosbuvir (Harvoni®)
|
Formulary
|
In line with NICE
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
|
Sofosbuvir (Sovaldi®)
|
Formulary
|
|
|
|
Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)
|
Formulary
|
In line with NICE
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
|
Sofosbuvir/velpatasvir (Epclusa®)
|
Formulary
|
In line with NICE
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
|
| 05.03.04 |
Influenza |
|
|
Oseltamivir
(Oral presentations)
|
First Choice
|
-For Primary Care- Green only during Flu season and on authorisation by NHS England/Department of Health & Social Care or via commissioned service for out of season supply
|
UKMI Q&A: Oseltamivir or zanamivir – can mothers breastfeed after treatment for influenza?
TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza
|
Oseltamivir (Tamiflu®)
(capsules & suspension SF)
|
First Choice
|
-For Primary Care- Green only during Flu season and on authorisation by NHS England/Department of Health & Social Care or via commissioned service for out of season supply
|
UKMI Q&A: Oseltamivir or zanamivir – can mothers breastfeed after treatment for influenza?
TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza
|
Zanamivir (Relenza®)
(dry powder for inhalation )
|
Second Choice
|
For Primary Care-Green only during Flu season and on authorisation by NHS England/Department of Health & Social Care or via commissioned service for out of season supply
|
UKM I Q&A: Oseltamivir or zanamivir – can mothers breastfeed after treatment for influenza?
TA 168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
|
Amantadine Hydrochloride
|
Formulary
|
|
|
|
Zanamivir Injection (Dectova ®)
|
Formulary
|
|
|
|
|
|
| 05.03.05 |
Respiratory syncytial virus |
|
|
Palivizumab (Synagis®)
(Injection)
|
Formulary
|
|
|
|
Ribavirin
(Tablet, Capsules & Inhalation)
|
Formulary
|
|
NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
|
| .... |
| Non Formulary Items |
Abacavir (Ziagen®)
|
Non Formulary
|
|
|
|
Abacavir and Lamivudine (Kivexa®)
(tablets)
|
Non Formulary
|
|
|
|
Abacavir and Lamivudine and Zidovudine (Trizivir®)
|
Non Formulary
|
|
|
|
Amantadine Hydrochloride (Symmetrel®)
|
Non Formulary
|
|
|
|
Amprenavir (Agenerase®)
|
Non Formulary
|
|
|
|
Darunavir (Prezista®)
(tablets)
|
Non Formulary
|
|
|
|
Didanosine (Videx®)
(capsules)
|
Non Formulary
|
|
|
|
Efavirenz
(Tablets)
|
Non Formulary
|
|
|
|
Efavirenz with emtricitabine and tenofovir disoproxil (Atripla® )
|
Non Formulary
|
|
|
|
Emtricitabine with tenofovir disoproxil (Ictastan®)
|
Non Formulary
|
|
|
|
Emtricitabine with tenofovir disoproxil (Truvada®)
|
Non Formulary
|
|
|
|
Fostemsavir (Rukobia®)
|
Non Formulary
|
|
|
|
Indinavir (Crixivan®)
|
Non Formulary
|
|
|
|
Nelfinavir
|
Non Formulary
|
|
|
|
Ritonavir (Norvir®)
(tablets & SF solution)
|
Non Formulary
|
|
|
|
Saquinavir (Invirase®)
(tablets)
|
Non Formulary
|
|
|
|
Stavudine
(capsules)
|
Non Formulary
|
|
|
|
Tenofovir Disproxil (Viread®)
|
Non Formulary
|
|
|
|
Tenofovir Disproxil (Viread®)
(tablets)
|
Non Formulary
|
|
NICE CG165: Hepatitis B (chronic) - diagnosis and management
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
|
test Chronic hepatitis C
|
Non Formulary
|
|
|
|
Tipranavir (Aptivus®)
|
Non Formulary
|
|
|
|
Zidovudine (Retrovir®)
(capsules )
|
Non Formulary
|
|
|
|
Zidovudine and Lamivudine (Combivir®)
(tablets)
|
Non Formulary
|
|
|
|
| |
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
|
